This news release is available in German.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will fund four new clinical trials following a decision by its Joint Committee. The trials will enable researchers to address current, urgent questions in patient-oriented clinical research within the framework of a controlled interventional trial. The topics of the new trials include surgery for metastatic cancer of the stomach, individualised chemotherapy for certain forms of breast cancer, the effect of growth factors in combating liver failure, and the testing of new psychological therapies for schizophrenia.
Over 1160 patients in more than 90 university clinics and other hospitals will participate in the trials. A total of 4.5 million euros is being made available for an initial period of three years, after which the researchers may apply for a renewal.
As a result, the DFG will be funding a total of 79 clinical trials. They are all prospective, interventional and confirmatory trials for new procedures. They also encompass therapeutic trials, including pharmacological trials ("therapeutic confirmatory"), as well as prognostic and diagnostic trials in phases II - IV, the aim of which is to test the efficacy of a new procedure. Trials must be carried out at multiple centres. They must be of high scientific quality and originality and clinically relevant.
The topics of the new clinical trials
(in alphabetical order by principal investigator)
Prof. Dr. med. Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt
Effect of the chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the AIO/CAO-V/CAOGI
PD Dr. med. Cornelius Engelmann, University Hospital Leipzig
Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicentre randomised trial (GRAFT Trial)
Prof. Dr. phil. Steffen Moritz, University Medical Center Hamburg-Eppendorf
Immediate and delayed effects of individualised metacognitive training for psychosis (MCT+)
Priv.-Doz. Dr. med. Kerstin Rhiem, University Hospital Cologne
A neoadjuvant phase II/III RCT for BRCA1/2-associated and familial triple negative breast cancer comparing carboplatin to docetaxel (neoFAM)
###
Further Information
Media contact:
DFG Press and Public Relations, Tel. +49 228 885-2443, presse@dfg.de
DFG programme contacts:
Dr. Frank Wissing, Tel. +49 228 885-2735, Frank.Wissing@dfg.de
Dr. Katja Großmann, Tel. +49 228 885-2565, Katja.Grossmann@dfg.de
Detailed information can also be provided by the principal investigators of the clinical trials.
For more information about the DFG's programme for clinical trials, please visit: http://www.dfg.de/en/research_funding/programmes/individual/clinical_trials